China's Tsingke Biotechnology secures $57m in Series B round

China's Tsingke Biotechnology secures $57m in Series B round

Photo by RephiLe on Unsplash

06 December, 2022

Tsingke Biotechnology

Printed by Unregistered user on Fri, 15 Aug 2025 18:27:40 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

You may also like

SAFE Pharma bags $72m and 36 other Greater China deals worth nearly $670m

Deal count soars in Q3, but fundraising falls YoY in Greater China

Read more from Greater China

Bridgewater sold all its US-listed China stocks, worth $1.5b, in Q2 2025

China’s Ant Group says Bright Smart acquisition on track following reports of delay